Document is current
Any future updates will be listed below
-
Authors
Ghisoni, Eleonora
Morotti, Matteo
Sarivalasis, Apostolos
Grimm, Alizée J.
Kandalaft, Lana http://orcid.org/0000-0002-1575-6674
Laniti, Denarda Dangaj
Coukos, George http://orcid.org/0000-0001-8813-7367
- License Information
-
More Information
Article History
Accepted: 12 August 2024
First Online: 4 September 2024
Competing interests
: M.M. is currently an employee of the CDR-Life company. A.S. has been a consultant and advisory board member for AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, GSK-Tesaro, MSD, Novartis, Roche and Seagen; received research support from AstraZeneca and Roche; and received institutional travel and congress support from Amgen, AstraZeneca, Celgene, Clovis, GSK-Tesaro, MSD, Novartis, Pfizer, Roche and Seagen. D.D.L. has received a grant from F. Hoffmann-La Roche AG. G.C. has received grants, research support or has been a co-investigator in clinical trials by Boehringer Ingelheim, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Iovance and Tigen Pharma. Lausanne University Hospital (CHUV) has received honoraria for advisory services that G.C. has provided to AstraZeneca, EVIR and Genentech. Patents related to the NeoTIL technology from the laboratory of G.C. have been licensed by the Ludwig Institute, on behalf of the University of Lausanne and the CHUV, to Tigen Pharma. G.C. has received royalties from the University of Pennsylvania for a CAR T cell product licensed to Novartis and Tmunity Therapeutics. E.G., A.J.G. and L.K. declare no competing interests.
